Trudy G Oliver

List of Publications by Year
in descending order

51 papers	4,643 citations	172457 29 h-index	289244 40 g-index
56 all docs	56 docs citations	56 times ranked	6307 citing authors

#	Article	IF	Citations
1	Killing SCLC: insights into how to target a shapeshifting tumor. Genes and Development, 2022, 36, 241-258.	5.9	26
2	TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene, 2022, 41, 3423-3432.	5.9	7
3	Inhibition of Karyopherin Î²1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. Cancer Research, 2022, 82, 3058-3073.	0.9	6
4	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. Journal of Clinical Investigation, 2021, 131, .	8.2	33
5	ASCL1 represses a SOX9⁺ neural crest stem-like state in small cell lung cancer. Genes and Development, 2021, 35, 847-869.	5.9	32
6	<i>Rlfâ€"Mycl</i> Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. Cancer Discovery, 2021, 11, 3214-3229.	9.4	24
7	Tumor heterogeneity. Cancer Cell, 2021, 39, 1015-1017.	16.8	66
8	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism, 2021, 9, 33.	5.0	20
9	Leveraging insights into cancer metabolismâ€"a symposium report. Annals of the New York Academy of Sciences, 2020, 1462, 5-13.	3.8	3
10	A Switch in p53 Dynamics Marks Cells That Escape from DSB-Induced Cell Cycle Arrest. Cell Reports, 2020, 32, 107995.	6.4	39
11	MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 2020, 38, 60-78.e12.	16.8	262
12	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
13	Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells. Molecular Oncology, 2020, 14, 686-703.	4.6	5
14	Neutrophils Create an ImpeNETrable Shield between Tumor and Cytotoxic Immune Cells. Immunity, 2020, 52, 729-731.	14.3	24
15	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
16	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
17	MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. Clinical Cancer Research, 2019, 25, 5107-5121.	7.0	117
18	Partners in Crime: Neutrophilâ€"CTC Collusion in Metastasis. Trends in Immunology, 2019, 40, 556-559.	6.8	19

#	Article	IF	Citations
19	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	28.4	692
20	Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Translational Lung Cancer Research, 2018, 7, 32-49.	2.8	173
21	The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity, 2018, 49, 764-779.e9.	14.3	138
22	Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. Nature Communications, 2018, 9, 3787.	12.8	112
23	Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. Cell Metabolism, 2018, 28, 369-382.e5.	16.2	136
24	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
25	Family matters: How MYC family oncogenes impact small cell lung cancer. Cell Cycle, 2017, 16, 1489-1498.	2.6	75
26	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget, 2017, 8, 73419-73432.	1.8	74
27	Sox2 cooperates with Lkb1 loss to promote squamous cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S11.	1.1	0
28	Squamous Nonâ€“small Cell Lung Cancer as a Distinct Clinical Entity. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 220-226.	1.3	25
29	Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. Cell Death and Differentiation, 2015, 22, 719-730.	11.2	43
30	Mighty mouse breakthroughs: a Sox2-driven model for squamous cell lung cancer. Molecular and Cellular Oncology, 2015, 2, e969651.	0.7	0
31	Sox2 Cooperates with Lkb1 Loss in a Mouse Model of Squamous Cell Lung Cancer. Cell Reports, 2014, 8, 40-49.	6.4	78
32	<i>RIG</i> -ging Biomarkers for Therapeutic Response. Science Translational Medicine, 2014, 6, .	12.4	0
33	Bosom Buddies: Close Connections Between Breast and Bladder Cancer. Science Translational Medicine, 2014, 6, .	12.4	0
34	<i>Pten</i>-Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction. Cancer Discovery, 2013, 3, 908-921.	9.4	36
35	Ovarian Stem Cells Find Their Niche. Science Translational Medicine, 2013, 5, .	12.4	0
36	Dangerous Liaisons: When Two Wrongs Just Might Make a Right. Science Translational Medicine, 2013, 5, .	12.4	0

#	Article	IF	Citations
37	A TWO Hit Wonder for Melanoma Treatment. Science Translational Medicine, 2013, 5, .	12.4	0
38	An Inferiority Complex for Chemo. Science Translational Medicine, 2013, 5, .	12.4	0
39	An Anti-Depressing Discovery for Lung Cancer Treatment. Science Translational Medicine, 2013, 5, .	12.4	0
40	Waking a Sleeping Giantâ€¦on Purpose?. Science Translational Medicine, 2013, 5, .	12.4	0
41	Abstract A35: The role of Mdm2 cleavage in p53 function and chemotherapy response. Clinical Cancer Research, 2012, 18, A35-A35.	7.0	0
42	Caspase-2-Mediated Cleavage of Mdm2 Creates a p53-Induced Positive Feedback Loop. Molecular Cell, 2011, 43, 57-71.	9.7	139
43	Response and Resistance to NF-Î°B Inhibitors in Mouse Models of Lung Adenocarcinoma. Cancer Discovery, 2011, 1, 236-247.	9.4	116
44	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 2010, 24, 837-852.	5.9	174
45	Suppression of Rev3, the catalytic subunit of PolÎ¶, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 20786-20791.	7.1	160
46	Impaired Bub1 Function <i>In vivo</i> Compromises Tension-Dependent Checkpoint Function Leading to Aneuploidy and Tumorigenesis. Cancer Research, 2009, 69, 45-54.	0.9	75
47	Aurora-A Kinase Is Essential for Bipolar Spindle Formation and Early Development. Molecular and Cellular Biology, 2009, 29, 1059-1071.	2.3	113
48	Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2973-2978.	7.1	126
49	Loss of<i>patched</i>and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development (Cambridge), 2005, 132, 2425-2439.	2.5	223
50	Getting at the Root and Stem of Brain Tumors. Neuron, 2004, 42, 885-888.	8.1	94
51	Transcriptional profiling of the Sonic hedgehog response: A critical role for N-myc in proliferation of neuronal precursors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7331-7336.	7.1	346